A novel PPARγ gene therapy to control inflammation associated with inflammatory bowel disease in a murine model
- 1 May 2003
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 124 (5) , 1315-1324
- https://doi.org/10.1016/s0016-5085(03)00262-2
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Interferon-γ-mediated Activation and Ubiquitin-Proteasome-dependent Degradation of PPARγ in AdipocytesJournal of Biological Chemistry, 2002
- PPARγ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's diseaseTrends in Molecular Medicine, 2001
- Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator–Activated Receptor γ (Pparγ) HeterodimerThe Journal of Experimental Medicine, 2001
- Increased sensitivity to dextran sodium sulfate colitis in IRE1β-deficient miceJournal of Clinical Investigation, 2001
- Efficient Gene Delivery into Dendritic Cells by Fiber-Mutant Adenovirus VectorsBiochemical and Biophysical Research Communications, 2001
- A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory responseJournal of Clinical Investigation, 1999
- A Simple Method for Constructing E1- and E1/E4-Deleted Recombinant Adenoviral VectorsHuman Gene Therapy, 1999
- Efficient Construction of a Recombinant Adenovirus Vector by an ImprovedIn VitroLigation MethodHuman Gene Therapy, 1998
- The use of adenoviral vectors for gene therapy and gene transfer in vivoCurrent Opinion in Biotechnology, 1995
- 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγCell, 1995